Edesa Biotech (EDSA) 10-Q 9 Feb 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Dec. 31, 2014	Feb. 01, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	Stellar Biotechnologies, Inc.
Entity Central Index Key	1540159
Entity Filer Category	Accelerated Filer
Trading Symbol	SBOTF
Amendment Flag	FALSE
Current Fiscal Year End Date	-21
Document Period End Date	31-Dec-14
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015
Document Type	10-Q
Entity Common Stock, Shares Outstanding		79,546,650

Condensed_Interim_Consolidated

Condensed Interim Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Sep. 30, 2014	Aug. 31, 2014
Current assets:
Cash and cash equivalents	$12,763,533	$13,769,953	$13,427,404
Accounts receivable	35,981	44,159	56,575
Short-term investments		448,632	458,098
Inventory	134,308	34,891
Prepaid expenses	86,417	125,840	128,593
Total current assets	13,020,239	14,423,475	14,070,670
Noncurrent assets:
Property, plant and equipment, net	389,654	388,340	387,392
Deposits	15,900	15,900	15,900
Total noncurrent assets	405,554	404,240	403,292
Total Assets	13,425,793	14,827,715	14,473,962
Current liabilities:
Accounts payable and accrued liabilities	550,574	585,047	526,626
Deferred revenue	86,667	86,667	15,000
Warrant liability, current portion	3,318,103	460	879,040
Total current liabilities	3,955,344	672,174	1,420,666
Long-term liabilities:
Warrant liability, less current portion	233,607	3,690,806	5,352,663
Total Liabilities	4,188,951	4,362,980	6,773,329
Commitments (Note 7)
Shareholders' equity:
Common shares, unlimited common shares authorized, no par value, 79,546,650, 79,419,850, and 78,268,850 issued and outstanding at December 31, September 30, and August 31, 2014, respectively	37,940,641	37,883,877	36,240,838
Accumulated share-based compensation	5,131,964	5,073,144	5,079,985
Accumulated deficit	-33,835,763	-32,492,286	-33,620,190
Total shareholders' equity	9,236,842	10,464,735	7,700,633
Total Liabilities and Shareholders' Equity	$13,425,793	$14,827,715	$14,473,962

Condensed_Interim_Consolidated1

Condensed Interim Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Sep. 30, 2014	Aug. 31, 2014
Condensed Interim Consolidated Balance Sheets [Abstract]
Common shares, par value
Common shares, shares issued	79,546,650	79,419,850	78,268,850
Common shares, shares outstanding	79,546,650	79,419,850	78,268,850

Condensed_Interim_Consolidated2

Condensed Interim Consolidated Statements of Operations (USD $)	1 Months Ended	3 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Contract services revenue	$20,000	$60,000	$15,000
Product sales	32,786	152,661	16,085
Grant revenue			27,740
Revenues	52,786	212,661	58,825
Expenses:
Costs of contract services	11,107	16,697	10,406
Costs of production and aquaculture	22,592	160,404	146,931
Grant costs			27,740
Research and development	178,280	418,821	548,225
General and administration	293,130	942,153	1,021,130
Total Expenses	505,109	1,538,075	1,754,432
Other Income (Loss)
Foreign exchange gain (loss)	-97,866	-161,112	-16,508
Increase (decrease) in fair value of warrant liability	1,680,040	139,556	-3,880,195
Investment income	1,853	13,293	15,920
Other Income (Loss), Total	1,584,027	-8,263	-3,880,783
Income (Loss) Before Income Tax	1,131,704	-1,333,677	-5,576,390
Income tax expense	3,800	9,800	800
Net Income (Loss)	$1,127,904	($1,343,477)	($5,577,190)
Income (loss) per common share - basic	$0.01	($0.02)	($0.08)
Income (loss) per common share - diluted	$0.01	($0.02)	($0.08)
Weighted average number of common shares outstanding, Basic	78,675,750	79,461,013	73,978,736
Weighted average number of common shares outstanding, Diluted	87,140,449	79,461,013	73,978,736

Condensed_Interim_Consolidated3

Condensed Interim Consolidated Statements of Cash Flows (USD $)	1 Months Ended	3 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Cash Flows Used In Operating Activities:
Net income (loss)	$1,127,904	($1,343,477)	($5,577,190)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	12,529	37,535	31,811
Share-based compensation	36,509	86,865	468,717
Foreign exchange (gain) loss	97,866	161,112	16,508
Change in fair value of warrant liability	-1,680,040	-139,556	3,880,195
Changes in working capital items:
Accounts receivable	12,352	8,045
Inventory	-34,891	-99,417	158,284
Prepaid expenses	490	36,469	2,101
Accounts payable and accrued liabilities	58,922	-33,120	-67,314
Deferred revenue	71,667
Net cash used in operating activities	-296,692	-1,285,544	-1,086,888
Cash Flows Used In Investing Activities:
Acquisition of property, plant and equipment	-13,477	-38,849	-209,129
Purchase of short-term investments	-2,491
Proceeds on maturities of short-term investments		442,911
Net cash provided by (used in) investing activities	-15,968	404,062	-209,129
Cash Flows From Financing Activities:
Proceeds from exercise of warrants and options	739,292	28,719	2,557,714
Net cash provided by financing activities	739,292	28,719	2,557,714
Effect of exchange rate changes on cash and cash equivalents	-84,083	-153,657	-14,165
Net change in cash and cash equivalents	342,549	-1,006,420	1,247,532
Cash and cash equivalents - beginning of year	13,427,404	13,769,953	15,478,038
Cash and cash equivalents - end of year	$13,769,953	$12,763,533	$16,725,570

Nature_of_Operations_and_Going

Nature of Operations and Going Concern	3 Months Ended
	Dec. 31, 2014
Nature of Operations and Going Concern [Abstract]
Nature of Operations and Going Concern		1	Nature of Operations and Going Concern
	Stellar Biotechnologies, Inc. (“the Company”) is organized under the laws of British Columbia, Canada. The Company's common shares are quoted on the U.S. OTCQB Marketplace Exchange under the trading symbol, SBOTF, and are listed on the TSX Venture Exchange as a Tier 2 issuer under the trading symbol, KLH.
	On April 7, 2010, the Company changed its name from CAG Capital, Inc. to Stellar Biotechnologies, Inc. On April 12, 2010, the Company completed a reverse merger transaction with Stellar Biotechnologies, Inc. a California corporation, which was founded in September 1999, and remains the Company's wholly-owned subsidiary and principal operating entity. The Company's executive offices are located at 332 E. Scott Street, Port Hueneme, California, 93041, USA, and its registered and records office is Royal Centre, 1055 West Georgia Street, Suite 1500, Vancouver, BC, V6E 4N7, Canada.
	Nature of Operations
	The Company's business is the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (“KLH”). The Company markets and distributes its KLH products to biotechnology and pharmaceutical companies, academic institutions, and clinical research organizations in Europe, United States, and Asia.
	Going Concern
	For the three months ended December 31, 2014 and 2013, the Company reported net losses of approximately $1.3 million and $5.6 million, respectively. For the one month ended September 30, 2014, the Company reported net income of approximately $1.1 million. The most significant factor in the fluctuations in net income and losses relates to noncash changes in the fair value of warrant liability, which was a gain of $139,556, a loss of $3,880,195 and a gain of $1,680,040 for the three months ended December 31, 2014 and 2013 and the one month ended September 30, 2014, respectively. As of December 31, 2014, the Company had an accumulated deficit of approximately $33.8 million and working capital of approximately $9.1 million.
	In the past, operations of the Company have primarily been funded by the issuance of common shares, exercise of warrants, grant revenues, contract services revenue, and product sales. In September 2013, the Company closed a private placement with gross proceeds of $12,000,000. Management believes these financial resources are adequate to support the Company's initiatives at the current level for the foreseeable future. Management is also continuing the ongoing effort toward expanding the customer base for existing marketed products, and the Company may seek additional financing alternatives, including nondilutive financing through grants, collaboration and licensing arrangements, and additional equity financing.
	The accompanying condensed interim consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business.
	Functional Currency
	The condensed interim consolidated financial statements of the Company are presented in U.S. dollars, unless otherwise stated, which is the Company's functional currency.

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Dec. 31, 2014
Basis of Presentation [Abstract]
Basis of Presentation		2	Basis of Presentation
	The accompanying unaudited condensed interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q. They do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP for complete financial statements. These condensed interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes contained in the Company's Annual Report on Form 10-K for the year ended August 31, 2014.
	The accompanying condensed interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stellar Biotechnologies, Inc. All significant intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments and accruals) considered necessary for a fair presentation of the results of operations for the period presented have been included in the interim period. Operating results for the three months ended December 31, 2014 are not necessarily indicative of the results that may be expected for other interim periods or the year ending September 30, 2015. The condensed interim consolidated financial data at August 31, 2014 is derived from audited financial statements included in the Company's Annual Report on Form 10-K for the year ended August 31, 2014, as filed on November 14, 2014 with the SEC.
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from these estimates.
	Change in Fiscal Year End
	On June 3, 2014, the Board of Directors of the Company approved a change in the Company's fiscal year end from August 31 to September 30 of each year. This change to the calendar quarter reporting cycle began September 1, 2014. As a result of the change, the Company had a one-month transition period from September 1, 2014 to September 30, 2014. The unaudited results for the one month ended September 30, 2014 are included in this report. The Company has also included selected unaudited results for the one month ended September 30, 2013 for comparative purposes in Note 12. The audited results for the one month ended September 30, 2014 will be included in the Company's Annual Report on Form 10-K for the fiscal year ending September 30, 2015, if not filed with the SEC prior thereto.
	In addition, the results for the quarter ended December 31, 2014 are compared with the results of the quarter ended December 31, 2013, which have been recast on a calendar quarter basis due to the change in the Company's fiscal year end from August 31 to September 30.

Significant_Accounting_Policie

Significant Accounting Policies	3 Months Ended
	Dec. 31, 2014
Significant Accounting Policies [Abstract]
Significant Accounting Policies	3	Significant Accounting Policies
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 creates a new topic in the ASC Topic 606 and establishes a new control-based revenue recognition model, changes the basis for deciding when revenue is recognized over time or at a point in time, provides new and more detailed guidance on specific topics, and expands and improves disclosures about revenue. In addition, ASU 2014-09 adds a new Subtopic to the Codification, ASC 340-40, Other Assets and Deferred Costs: Contracts with Customers, to provide guidance on costs related to obtaining a contract with a customer and costs incurred in fulfilling a contract with a customer that are not in the scope of another ASC Topic. The guidance in ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2016, including interim periods therein. Early application is not permitted. Management is in the process of assessing the impact of ASU 2014-09 on the Company's financial statements.
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 defines management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. The guidance in ASU 2014-15 is effective for annual reporting periods beginning after December 15, 2016, with early application permitted. Management is in the process of assessing the impact of ASU 2014-15 on the Company's financial statements.

Inventory

Inventory	3 Months Ended
	Dec. 31, 2014
Inventory [Abstract]
Inventory	4	Inventory
	The Company records inventory for custom manufacturing of products for specific customers, including manufacturing under supply agreements. Raw materials include inventory of manufacturing supplies. Work in process includes manufacturing supplies, direct and indirect labor and allocated manufacturing overhead for custom manufacturing in process at the end of the period. There are no finished goods since once the custom manufacturing is complete, goods are shipped to the customer and removed from inventory. Inventory consisted of the following at December 31 and September 30, 2014. There was no inventory for custom manufactured products at August 31, 2014.
			December 31,		September 30,
			2014		2014
	Raw materials		$	15,212	$	10,480
	Work in process			119,096		24,411
			$	134,308	$	34,891

Property_Plant_and_Equipment_n

Property, Plant and Equipment, net	3 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment, net [Abstract]
Property, Plant and Equipment, net		5	Property, Plant and Equipment, net
	Property, plant and equipment, net consisted of the following:
			December 31,			September 30,			August 31,
			2014			2014			2014
	Aquaculture system		$	58,923		$	58,923		$	58,923
	Laboratory facilities			62,033			62,033			62,033
	Computer and office equipment			77,697			77,697			77,697
	Tools and equipment			635,766			635,766			622,289
	Vehicles			10,997			10,997			10,997
	Leasehold improvements			100,036			61,187			61,187
				945,452			906,603			893,126
	Less: accumulated depreciation			(555,798	)		(518,263	)		(505,734	)
			$	389,654		$	388,340		$	387,392
	Depreciation expense amounted to $37,535, $24,668 and $12,529 for the three months ended December 31, 2014 and 2013 and the one month ended September 30, 2014, respectively.

Intangible_Assets_Licensing_Ri

Intangible Assets - Licensing Rights	3 Months Ended
	Dec. 31, 2014
Intangible Assets - Licensing Rights [Abstract]
Intangible Assets - Licensing Rights		6	Intangible Assets - Licensing Rights
	In December 2010, the Company entered into a research collaboration agreement with a customer. When the agreement terminated according to its terms in August 2011, the Company acquired an exclusive, worldwide sub-licensable and royalty-free license for certain technology developed in collaboration with the customer. The Company paid a $200,000 license fee for the licensing rights, which are jointly owned by the Company and the customer. The licensing rights do not have a fixed term or termination provisions. The licensing rights are amortized over the estimated useful life of seven years and are shown net of accumulated amortization and impairment losses. During the year ended August 31, 2014, the Company discontinued its use of these licensing rights and recorded impairment loss for the remaining value of licensing rights.
	Amortization expense amounted to $7,143 for the three months ended December 31, 2013.

Commitments

Commitments	3 Months Ended
	Dec. 31, 2014
Commitments [Abstract]
Commitments	7	Commitments
	Operating leases
	The Company leases three buildings and facilities used in its operations under sublease agreements with the Port Hueneme Surplus Property Authority. In September 2010, the Company exercised its option to extend these sublease agreements for an additional five-year term. The Company has an option to extend the lease for a second additional five-year term.
	The Company also leases facilities used for executive offices and laboratories. The Company must pay a portion of the common area maintenance. In July 2014, the Company exercised its option to extend this lease for a two-year term.
	Future minimum lease payments are as follows:
			December 31,
			2014
	For The Year Ending September 30,
	2015		$	118,000
	2016			59,000
			$	177,000
	Rent expense on these lease agreements amounted to approximately $46,000, $45,000, and $15,000 for the three months ended December 31, 2014 and 2013, and the one month ended September 30, 2014, respectively.
	Purchase obligations
	The Company has commitments totaling approximately $60,000 at December 31, 2014, for signed agreements with contract research organizations and consultants, which are scheduled to be paid in accordance with contract terms during the 2015 fiscal year.
	Supply agreements
	The Company has four commitments under certain supply agreements with customers for fixed prices per gram on a non-exclusive basis except within that customer's field of use. Two agreements automatically renew each January unless terminated in writing by either party. One agreement is effective through  October 2019 and is renewable for one-year terms upon written request of the customer. One agreement is effective through October 2017 and is renewable for one-year terms upon written request of the customer.
	Licensing fees
	In July 2013, the Company acquired the exclusive, worldwide license to certain patented technology for the development of human immunotherapies against Clostridium difficile infection (“C. diff”). The license agreement required an initial, non-refundable license fee of $25,000, which was paid in fiscal August 2013, and payment of an aggregate of $200,000 in delayed license fees, which were paid in fiscal August 2014. Beginning September 2014, the terms also require a license fee of $20,000 to be paid annually, creditable against royalties due, if any. Royalties are payable for a percentage of related net sales, if any. License fees are also payable for a percentage of related non-royalty sublicensing revenue, if any. No royalties have been paid to date. The Company also reimbursed patent filing costs of approximately $11,000 and $12,000 in the three months ended December 31, 2014 and 2013, respectively, and will reimburse certain future patent filing, prosecution, and maintenance costs. There were no reimbursed patent filing costs during the one month ended September 30, 2014. License fees and patent cost reimbursements paid during the three months ended December 31, 2014 and 2013, and the one month ended September 30, 2014, have been accounted for as research and development expense in the accompanying condensed interim consolidated statements of operations.
	The license agreement expires when the last valid patent claim licensed under the license agreement expires. Prior to that time, the license agreement can be terminated by the licensor upon certain conditions. The Company will have 30 days after written notice from the licensor to cure the problem prior to termination of the license agreement. The Company can terminate the agreement with three months' prior written notice.
	Upon execution of the license agreement, the Company issued 371,200 common shares and warrants to purchase up to 278,400 of the Company's common shares to the licensor. The warrants expired on January 23, 2015 and were not exercised.
	The license agreement provides for the Company to pay up to an aggregate of $6,020,000 in milestone payments to the licensor upon achievement of various financing and development targets up to the first regulatory approval. Remaining contingent milestone payments to the licensor totaling $57,025,000 are related to achievement of sales targets. A financing milestone was met during the year ended August 31, 2014, and accordingly, the Company made a milestone payment of $100,000. No milestones were met during the three months ended December 31, 2014 and 2013, and the one month ended September 30, 2014, and there can be no assurance that any of the remaining milestones will be met in the future.
	Retirement savings plan 401(k) contributions
	The Company sponsors a 401(k) retirement savings plan that requires an annual non-elective safe harbor employer contribution of 3% of eligible employee wages. All employees over 21 years of age are eligible beginning the first payroll after 3 consecutive months of employment. Employees are 100% vested in employer contributions and in any voluntary employee contributions. Contributions to the 401(k) plan were approximately $20,000, $16,000 and $5,000 for the three months ended December 31, 2014 and 2013, and the one month ended September 30, 2014, respectively.
	Related party commitments
	See Note 9.

Share_Capital

Share Capital	3 Months Ended
	Dec. 31, 2014
Share Capital [Abstract]
Share Capital		8	Share Capital
	The Company had the following transactions in share capital:
			Three Months Ended								One Month Ended
			December 31,				December 31,				September 30,
			2014				2013				2014
	Proceeds from exercise of warrants and broker units		$	938			$	2,419,745			$	727,804
	Transfer to common shares on exercise of warrants and broker units			426				5,035,567				890,214
	Proceeds from exercise of options			27,781				137,969				11,488
	Transfer to common shares on exercise of options			27,619				142,405				13,533
	Share-based compensation			86,865				468,717				36,509
	Number of common shares issued			126,800				4,217,101				1,151,000
	Performance shares
	There were 10,000,000 common shares allotted as performance shares to be issued to certain officers, directors and employees of the Company based on meeting milestones related to completion of method development for commercial-scale manufacture of KLH, compilation and regulatory submittal of all required chemistry, manufacturing and control data and completion of preclinical toxicity and immunogenicity testing of products under a performance share plan. Share-based compensation was recorded over the estimated vesting period ending in August 2012.
	At December 31, 2014, there are 3,838,383 performance shares reserved for issuance.
	Black-Scholes option valuation model
	The Company uses the Black-Scholes option valuation model to determine the fair value of warrants, broker units and stock options. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company has used historical volatility to estimate the volatility of the share price. Changes in the subjective input assumptions can materially affect the fair value estimates, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company's warrants, broker units and stock options.
	Warrants
	A summary of the Company's warrants activity is as follows:
			Number of Warrants				Weighted
							Average
							Exercise Price
	Balance - August 31, 2013			11,326,300			$	0.57			CDN $
	Granted			38,100				0.46			CDN $
	Granted			6,047,612				1.33
	Exercised			(5,832,300	)			0.68			CDN $
	Exercised			(60,000	)			1.35
	Balance - August 31, 2014			11,519,712			$	0.97			CDN $
	Granted			42,600				0.75			CDN $
	Exercised			(1,017,000	)			0.75			CDN $
	Balance - September 30, 2014			10,545,312			$	1.01			CDN $
	Exercised			(600	)			0.75			CDN $
	Expired			(300	)			0.75			CDN $
	Balance - December 31, 2014			10,544,412			$	1.04			CDN $
	The weighted average contractual life remaining on the outstanding warrants at December 31, 2014 is 1.30 years.
	The following table summarizes information about the outstanding warrants at December 31, 2014:
	Exercise Price		Number of				Expiry Date
			Warrants
	CDN$1.25			278,400			23-Jan-15
	CDN$0.40			4,000,000			25-Oct-15
	CDN$0.40			278,400			4-Jan-16
	$1.35			4,701,902			9-Sep-16
	$1.05			200,000			9-Sep-16		Broker warrants
	$1.35			952,377			20-Sep-16
	$1.05			133,333			20-Sep-16		Broker warrants
				10,544,412
	Warrant liability
	Equity offerings conducted by the Company in prior years included the issuance of warrants with exercise prices denominated in Canadian dollars. The Company's functional currency is the U.S. dollar. As a result of having exercise prices denominated in other than the Company's functional currency, these warrants meet the definition of derivatives and are therefore classified as derivative liabilities measured at fair value with adjustments to fair value recognized through the consolidated statements of operations. As these warrants are exercised, the fair value of the recorded warrant liability on date of exercise is included in common shares along with the proceeds from the exercise. If these warrants expire, the related decrease in warrant liability is recognized in profit or loss, as part of the change in fair value of warrant liability. There is no cash flow impact as a result of this accounting treatment.
	The fair value of the warrants is determined using the Black-Scholes option valuation model at the end of each reporting period. Upon exercise of the warrants, the fair value of warrants included in derivative liabilities is reclassified to equity.
	The fair value of warrants exercised during the three months ended December 31, 2014 and 2013 and the one month ended September 30, 2014 was determined using the Black-Scholes option valuation model, using the following weighted average assumptions:
			Three Months Ended								One Month Ended
			December 31,				December 31,				September 30,
			2014				2013				2014
	Risk free interest rate			1.12	%			1.07	%			1.12	%
	Expected life (years)			0.01				0.25				0.03
	Expected share price volatility			97	%			111	%			97	%
	There were no warrants granted during the three months ended December 31, 2014 and 2013 and the one month ended September 30, 2014.
	Broker units
	The Company granted broker units as finders' fees in conjunction with equity offerings in prior years. Broker units are fully vested when granted and allow the holders to purchase equity units. A unit consists of one common share and either one whole warrant or one half warrant.
	A summary of broker units activity is as follows:
			Number of				Weighted
			Units				Average
							Exercise Price
	Balance - August 31, 2013			596,200			$	0.29			CDN $
	Exercised			(45,000	)			0.33			CDN $
Balance - August 31, 2014			551,200			$	0.29			CDN $
Exercised			(84,000	)			0.5			CDN $
Balance - September 30, 2014			467,200			$	0.25			CDN $
Exercised			(1,200	)			0.5			CDN $
Balance - December 31, 2014			466,000			$	0.25			CDN $
The weighted average contractual life remaining on the outstanding broker units is 0.84 years.
The following table summarizes information about the outstanding broker units at December 31, 2014:
Exercise Price		Number of				Expiry Date
		Units
CDN$0.25			400,000			25-Oct-15
CDN$0.25			66,000			4-Jan-16
			466,000
The outstanding broker units at December 31, 2014 include one warrant.
There were no broker units granted during the three months ended December 31, 2014 and 2013 and the one month ended September 30, 2014.
Options
The Company has a 2013 fixed stock option plan (“the Plan”) administered by the Board of Directors, who have the discretion to grant up to an aggregate of 10,000,000 options. The exercise price of an option is set at the closing price of the Company's common shares on the date of grant. Stock options granted to directors, officers, employees and consultants are subject to the following vesting schedule:
(a) One-third of the shares subject to the option shall vest immediately;
(b) One-third of the shares subject to the option shall vest 12 months from the date of grant; and
(c) One-third of the shares subject to the option shall vest 18 months from the date of grant.
Stock options granted to investor relations consultants vest over a period of not less than 12 months with 25% of the shares subject to the option vesting on the date that is three months from the date of grant, and a further 25% vesting on each successive date that is three months from the date of the prior vesting.
Options have been granted under the Plan allowing the holders to purchase common shares of the Company as follows:
		Number of				Weighted
		Options				Average
						Exercise Price
Balance - August 31, 2013			6,588,868			$	0.42			CDN $
Granted			195,000				1.42			CDN $
Granted			595,000				1.83
Exercised			(1,441,668	)			0.41			CDN $
Expired			(1,667	)			0.42			CDN $
Balance - August 31, 2014			5,935,533			$	0.61			CDN $
Exercised			(50,000	)			0.25			CDN $
Balance - September 30, 2014			5,885,533			$	0.62			CDN $
Granted			102,500				1.52			CDN $
Exercised			(125,000	)			0.25			CDN $
Balance - December 31, 2014			5,863,033			$	0.65			CDN $
The weighted average contractual life remaining on the outstanding options is 3.94 years.
The following table summarizes information about the options under the Plan outstanding and exercisable at December 31, 2014:
Exercise Price				Number of				Exercisable at				Expiry Date
				Options				31-Dec-14
CDN$	0.28				1,645,000				1,645,000			9-Apr-17
CDN$	0.25				55,000				55,000			17-May-17
CDN$	0.28				20,000				20,000			28-Jun-17
CDN$	0.28				70,000				70,000			13-Jul-17
CDN$	0.64				70,000				70,000			25-Oct-17
CDN$	1				60,000				60,000			10-Feb-18
CDN$	0.65				848,600				848,600			8-Aug-18
CDN$	0.5				5,000				5,000			26-Sep-18
CDN$	1.87				100,000				66,667			7-Nov-18
CDN$	0.4				70,000				70,000			22-Dec-18
CDN$	0.42				853,600				853,600			13-Apr-19
CDN$	0.29				90,000				90,000			18-Jun-19
CDN$	0.37				150,000				150,000			9-Aug-19
CDN$	0.37				150,000				150,000			16-Aug-19
CDN$	0.25				8,333				8,333			23-Oct-19
CDN$	0.25				215,000				215,000			19-Dec-19
CDN$	0.58				560,000				560,000			14-May-20
CDN$	0.58				100,000				100,000			23-May-20
$	1.83				495,000				330,000			1-Nov-20
$	1.84				100,000				66,667			15-Nov-20
CDN$	0.94				95,000				31,667			27-Jun-21
CDN$	1.52				102,500				34,167			12-Nov-21
					5,863,033				5,499,701
The estimated fair value of the stock options granted during the three months ended December 31, 2014 and 2013 was determined using a Black-Scholes option valuation model with the following weighted average assumptions. There were no stock options granted during the one month ended September 30, 2014.
		Three Months Ended
		December 31,				December 31,
		2014				2013
Risk free interest rate			1.71	%			1.98	%
Expected life (years)			7				6.42
Expected share price volatility			116	%			120	%
Expected dividend yield			0	%			0	%
The weighted average fair value of stock options awarded during the three months ended December 31, 2014 and 2013 was CDN$1.34 and CDN$1.49, respectively. There were no stock options awarded during the one month ended September 30, 2014.
As of December 31, 2014, the Company had approximately $175,000 of unrecognized share-based compensation expense, which is expected to be recognized over a period of 1.50 years.
The intrinsic value of the options exercised during the three months ended December 31, 2014 and 2013 and the one month ended September 30, 2014 was $1.15, $1.55, and $1.74, respectively. The intrinsic value of the vested options at December 31, 2014 was $0.83.

Related_Party_Disclosures

Related Party Disclosures	12 Months Ended
	Aug. 31, 2014
Related Party Disclosures [Abstract]
Related Party Disclosures	9	Related Party Disclosures
	Royalty agreement
	On August 14, 2002, through its California subsidiary, the Company entered into an agreement with a director and officer of the Company, where he would receive royalty payments in exchange for assignment of his patent rights to the Company. The royalty is 5% of gross receipts from products using this invention in excess of $500,000 annually. The Company's current operations utilize this invention. There was no royalty expense incurred during the three months ended December 31, 2014 and 2013, and the one month ended September 30, 2014.
	Collaboration agreement
	In December 2013, the Company entered into a collaboration agreement with a privately-held Taiwan biopharmaceuticals manufacturer and a beneficial owner of over 5% of the Company's common shares. Under the terms of the agreement, the Company will be responsible for the production and delivery of GMP grade KLH for evaluation as a carrier molecule in the collaboration partner's potential manufacture of OBI-822 active immunotherapy. The Company is also responsible for method development, product formulation, and process qualification for certain KLH reference standards. The collaboration partner is responsible for development objectives and product specifications. The agreement provides for the collaboration partner to pay fees for certain expenses and costs associated with the collaboration. Subject to certain conditions and timing, the collaboration also provides for the parties to negotiate a commercial supply agreement for Stellar KLH™ in the future. However, there can be no assurance that any such negotiations will lead to successful execution of any further agreements related to this collaboration.

Supplemental_Disclosure_of_Cas

Supplemental Disclosure of Cash Flow and Non-Cash Transactions	3 Months Ended
	Dec. 31, 2014
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Supplemental Disclosure of Cash Flow and Non-Cash Transactions		10	Supplemental Disclosure of Cash Flow and Non-Cash Transactions
	Supplemental disclosure of cash flow information follows:
			December 31,		December 31,		September 30,
			2014		2013		2014
	Cash paid during the period for taxes		$	9,800	$	800	$	800
	Cash paid during the period for interest			-		-		-
	Supplemental disclosure of non-cash financing and investing activities follows:
			December 31,		December 31,		September 30,
			2014		2013		2014
	Transfer to common stock on exercise of warrants and broker units		$	426		5,035,567		890,214
	Transfer to common stock on exercise of options			27,619		142,405		13,533
	Shares subscribed transferred to common stock			-		77,736		-

Concentrations_of_Credit_Risk

Concentrations of Credit Risk	12 Months Ended
	Aug. 31, 2014
Concentrations of Credit Risk [Abstract]
Concentrations of Credit Risk		11	Concentrations of Credit Risk
	Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash, cash equivalents and accounts receivable. Management's assessment of the Company's credit risk for cash and cash equivalents is low as cash and cash equivalents are held in financial institutions believed to be credit worthy. The Company limits its exposure to credit loss by placing its cash with major financial institutions and invests only in short-term obligations.
	Approximately 71%, 68% and 74% of the Company's product sales and contract services revenue during the three months ended December 31, 2014 and 2013, and the one month ended September 30, 2014, respectively, were from two customers. All of the grant revenue during the three months ended December 31, 2013 was received from the National Science Foundation.
	Approximately 73% and 76% of the Company's accounts receivable at December 31, 2014 and August 31, 2014, respectively, were from one customer and approximately 81% of the Company's accounts receivable at September 30, 2014 was from two customers.
	While the Company is exposed to credit losses due to the non-performance of its counterparties, the Company considers the risk of this remote. The Company estimates its maximum credit risk for accounts receivable at the amount recorded on the balance sheet.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2014
Significant Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 creates a new topic in the ASC Topic 606 and establishes a new control-based revenue recognition model, changes the basis for deciding when revenue is recognized over time or at a point in time, provides new and more detailed guidance on specific topics, and expands and improves disclosures about revenue. In addition, ASU 2014-09 adds a new Subtopic to the Codification, ASC 340-40, Other Assets and Deferred Costs: Contracts with Customers, to provide guidance on costs related to obtaining a contract with a customer and costs incurred in fulfilling a contract with a customer that are not in the scope of another ASC Topic. The guidance in ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2016, including interim periods therein. Early application is not permitted. Management is in the process of assessing the impact of ASU 2014-09 on the Company's financial statements.
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 defines management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. The guidance in ASU 2014-15 is effective for annual reporting periods beginning after December 15, 2016, with early application permitted. Management is in the process of assessing the impact of ASU 2014-15 on the Company's financial statements.

Inventory_Tables

Inventory (Tables)	3 Months Ended
	Dec. 31, 2014
Inventory [Abstract]
Inventory		December 31,		September 30,
		2014		2014
	Raw materials	$	15,212	$	10,480
	Work in process		119,096		24,411
		$	134,308	$	34,891

Property_Plant_and_Equipment_n1

Property, Plant and Equipment, net (Tables)	3 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment, net [Abstract]
Property, Plant and Equipment, net	Property, plant and equipment, net consisted of the following:
		December 31,			September 30,			August 31,
		2014			2014			2014
	Aquaculture system	$	58,923		$	58,923		$	58,923
	Laboratory facilities		62,033			62,033			62,033
	Computer and office equipment		77,697			77,697			77,697
	Tools and equipment		635,766			635,766			622,289
	Vehicles		10,997			10,997			10,997
	Leasehold improvements		100,036			61,187			61,187
			945,452			906,603			893,126
	Less: accumulated depreciation		(555,798	)		(518,263	)		(505,734	)
		$	389,654		$	388,340		$	387,392

Commitments_Tables

Commitments (Tables)	3 Months Ended
	Dec. 31, 2014
Commitments [Abstract]
Schedule of Future Minimum Lease Payments	Future minimum lease payments are as follows:
		December 31,
		2014
	For The Year Ending September 30,
	2015	$	118,000
	2016		59,000
		$	177,000

Share_Capital_Tables

Share Capital (Tables)	3 Months Ended
	Dec. 31, 2014
Share Capital [Abstract]
Transactions In Share Capital	The Company had the following transactions in share capital:
			Three Months Ended								One Month Ended
			December 31,				December 31,				September 30,
			2014				2013				2014
	Proceeds from exercise of warrants and broker units		$	938			$	2,419,745			$	727,804
	Transfer to common shares on exercise of warrants and broker units			426				5,035,567				890,214
	Proceeds from exercise of options			27,781				137,969				11,488
	Transfer to common shares on exercise of options			27,619				142,405				13,533
	Share-based compensation			86,865				468,717				36,509
	Number of common shares issued			126,800				4,217,101				1,151,000
Schedule of Warrant Activity	A summary of the Company's warrants activity is as follows:
			Number of				Weighted
			Warrants				Average
							Exercise Price
	Balance - August 31, 2013			11,326,300			$	0.57			CDN $
	Granted			38,100				0.46			CDN $
	Granted			6,047,612				1.33
	Exercised			(5,832,300	)			0.68			CDN $
	Exercised			(60,000	)			1.35
	Balance - August 31, 2014			11,519,712			$	0.97			CDN $
	Granted			42,600				0.75			CDN $
	Exercised			(1,017,000	)			0.75			CDN $
	Balance - September 30, 2014			10,545,312			$	1.01			CDN $
	Exercised			(600	)			0.75			CDN $
	Expired			(300	)			0.75			CDN $
	Balance - December 31, 2014			10,544,412			$	1.04			CDN $
Summary of Warrants Outstanding	The following table summarizes information about the outstanding warrants at December 31, 2014:
	Exercise Price		Number of				Expiry Date
			Warrants
	CDN$1.25			278,400			23-Jan-15
	CDN$0.40			4,000,000			25-Oct-15
	CDN$0.40			278,400			4-Jan-16
	$1.35			4,701,902			9-Sep-16
	$1.05			200,000			9-Sep-16		Broker warrants
	$1.35			952,377			20-Sep-16
	$1.05			133,333			20-Sep-16		Broker warrants
				10,544,412
Schedule of Fair Value Of Warrants Exercised, Valuation Assumptions	The fair value of warrants exercised during the three months ended December 31, 2014 and 2013, and the one month ended September 30, 2014 was determined using the Black-Scholes option valuation model, using the following weighted average assumptions:
			Three Months Ended								One Month Ended
			December 31,				December 31,				September 30,
			2014				2013				2014
	Risk free interest rate			1.12	%			1.07	%			1.12	%
	Expected life (years)			0.01				0.25				0.03
	Expected share price volatility			97	%			111	%			97	%
Schedule of Broker Units Activity	A summary of broker units activity is as follows:
			Number of				Weighted
			Units				Average
							Exercise Price
	Balance - August 31, 2013			596,200			$	0.29			CDN $
	Exercised			(45,000	)			0.33			CDN $
	Balance - August 31, 2014			551,200			$	0.29			CDN $
	Exercised			(84,000	)			0.5			CDN $
	Balance - September 30, 2014			467,200			$	0.25			CDN $
	Exercised			(1,200	)			0.5			CDN $
	Balance - December 31, 2014			466,000			$	0.25			CDN $
Summary Of Broker Units Outstanding	The following table summarizes information about the outstanding broker units at December 31, 2014:
	Exercise Price		Number of				Expiry Date
			Units
	CDN$0.25			400,000			25-Oct-15
	CDN$0.25			66,000			4-Jan-16
				466,000
Schedule of Share-based Compensation Stock Options Activity	Options have been granted under the Plan allowing the holders to purchase common shares of the Company as follows:
			Number of				Weighted
			Options				Average
							Exercise Price
	Balance - August 31, 2013			6,588,868			$	0.42			CDN $
	Granted			195,000				1.42			CDN $
	Granted			595,000				1.83
	Exercised			(1,441,668	)			0.41			CDN $
	Expired			(1,667	)			0.42			CDN $
	Balance - August 31, 2014			5,935,533			$	0.61			CDN $
	Exercised			(50,000	)			0.25			CDN $
	Balance - September 30, 2014			5,885,533			$	0.62			CDN $
	Granted			102,500				1.52			CDN $
	Exercised			(125,000	)			0.25			CDN $
	Balance - December 31, 2014			5,863,033			$	0.65			CDN $
Summary of Options Outstanding And Exercisable	The following table summarizes information about the options under the Plan outstanding and exercisable at December 31, 2014:
	Exercise Price				Number of				Exercisable at				Expiry Date
					Options				31-Dec-14
	CDN$	0.28				1,645,000				1,645,000			9-Apr-17
	CDN$	0.25				55,000				55,000			17-May-17
	CDN$	0.28				20,000				20,000			28-Jun-17
	CDN$	0.28				70,000				70,000			13-Jul-17
	CDN$	0.64				70,000				70,000			25-Oct-17
	CDN$	1				60,000				60,000			10-Feb-18
	CDN$	0.65				848,600				848,600			8-Aug-18
	CDN$	0.5				5,000				5,000			26-Sep-18
	CDN$	1.87				100,000				66,667			7-Nov-18
	CDN$	0.4				70,000				70,000			22-Dec-18
	CDN$	0.42				853,600				853,600			13-Apr-19
	CDN$	0.29				90,000				90,000			18-Jun-19
	CDN$	0.37				150,000				150,000			9-Aug-19
	CDN$	0.37				150,000				150,000			16-Aug-19
	CDN$	0.25				8,333				8,333			23-Oct-19
	CDN$	0.25				215,000				215,000			19-Dec-19
	CDN$	0.58				560,000				560,000			14-May-20
	CDN$	0.58				100,000				100,000			23-May-20
	$	1.83				495,000				330,000			1-Nov-20
	$	1.84				100,000				66,667			15-Nov-20
	CDN$	0.94				95,000				31,667			27-Jun-21
	CDN$	1.52				102,500				34,167			12-Nov-21
						5,863,033				5,499,701
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The estimated fair value of the stock options granted during the three months ended December 31, 2014 and 2013 was determined using a Black-Scholes option valuation model with the following weighted average assumptions. There were no stock options granted during the one month ended September 30, 2014.
			Three Months Ended
			December 31,				December 31,
			2014				2013
	Risk free interest rate			1.71	%			1.98	%
	Expected life (years)			7				6.42
	Expected share price volatility			116	%			120	%
	Expected dividend yield			0	%			0	%

Supplemental_Disclosure_of_Cas1

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Tables)	3 Months Ended
	Dec. 31, 2014
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Supplemental Disclosure of Cash Flow Information	Supplemental disclosure of cash flow information follows:
		December 31,		December 31,		September 30,
		2014		2013		2014
	Cash paid during the period for taxes	$	9,800	$	800	$	800
	Cash paid during the period for interest		-		-		-
Supplemental Disclosure of Non-Cash Financing and Investing Activities	Supplemental disclosure of non-cash financing and investing activities follows:
		December 31,		December 31,		September 30,
		2014		2013		2014
	Transfer to common stock on exercise of warrants and broker units	$	426		5,035,567		890,214
	Transfer to common stock on exercise of options		27,619		142,405		13,533
	Shares subscribed transferred to common stock		-		77,736		-

Condensed_Transition_Period_Co

Condensed Transition Period Comparable Year Financial Information (Tables)	3 Months Ended
	Dec. 31, 2014
Condensed Transition Period Comparable Year Financial Information [Abstract]
Condensed Transition Period Comparable Year Balance Sheets [Table Text Block]		September 30,
		2013
	Assets:
	Cash and cash equivalents	$	15,478,038
	Other current assets		225,713
	Noncurrent assets		368,232
	Total Assets	$	16,071,983
	Liabilities and Shareholders' Equity
	Accounts payable, accrued liabilities and deferred revenue	$	649,113
	Warrant liability, including current portion		8,886,084
	Shareholders' equity		6,536,786
	Total Liabilities and Shareholders' Equity	$	16,071,983
Condensed Transition Period Comparable Year Statements Of Operations [Table Text Block]		One Month Ended
		September 30,
		2013
	Total Revenues	$	13,839
	Expenses:
	Costs of revenues		34,930
	Research and development		203,367
	General and administration		112,892
	Total Expenses		351,189
	Other Income (Loss):
	Foreign exchange gain (loss)		(106,446	)
	Change in fair value of warrant liability		203,021
	Other income		386
	Income tax expense		-
	Net Loss	$	(240,389	)
	Loss per common share - basic and diluted	$	(0.00	)
	Weighted average number of common shares outstanding		65,873,540
Condensed Transition Period Comparable Year Statements Of Cash Flow [Table Text Block]		One Month Ended
		September 30,
		2013
	Cash Flows Used In Operating Activities:
	Net loss	$	(240,389	)
	Adjustments and changes in working capital items		240,023
	Net cash used in operating activities		(366	)
	Net cash used in investing activities		-
	Net cash provided by financing activities		7,722,346
	Effect of exchange rate changes on cash and cash equivalents		(103,831	)
	Net change in cash and cash equivalents		7,618,149
	Cash and cash equivalents - beginning of period		7,859,889
	Cash and cash equivalents - end of period	$	15,478,038
Condensed Transition Period Comparable Year Share Capital Transactions [Table Text Block]		One Month Ended
		September 30,
		2013
	Share Capital Transactions:
	Proceeds of private placements, net of issuance costs	$	6,560,833
	Proceeds from exercise of warrants and broker units		993,243
	Transfer to common shares on exercise of warrants and broker units		1,212,985
	Proceeds from exercise of options		168,270
	Transfer to common shares on exercise of options		147,542
	Share-based compensation		77,736
	Number of common shares issued		13,701,770

Nature_of_Operations_and_Going1

Nature of Operations and Going Concern (Details) (USD $)	1 Months Ended		3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2014
Nature of Operations and Going Concern [Abstract]
Net income (loss)	$1,127,904	($240,389)	($1,343,477)	($5,577,190)
Accumulated deficit	-32,492,286		-33,835,763		-33,620,190
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net	1,680,040	203,021	139,556	-3,880,195
Proceeds from a private placement		$12,000,000

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2014	Sep. 30, 2014	Aug. 31, 2014
Inventory [Abstract]
Raw materials	$15,212	$10,480
Work in process	119,096	24,411
Inventory	$134,308	$34,891

Property_Plant_and_Equipment_n2

Property, Plant and Equipment, net (Narrative) (Details) (USD $)	1 Months Ended	3 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment, net [Abstract]
Depreciation expense	$12,529	$37,535	$24,668

Property_Plant_and_Equipment_n3

Property, Plant and Equipment, net (Details) (USD $)	Dec. 31, 2014	Sep. 30, 2014	Aug. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$945,452	$906,603	$893,126
Less: accumulated depreciation	-555,798	-518,263	-505,734
Property, Plant and Equipment, net	389,654	388,340	387,392
Aquaculture system [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	58,923	58,923	58,923
Laboratory facilities [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	62,033	62,033	62,033
Computer and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	77,697	77,697	77,697
Tools and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	635,766	635,766	622,289
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	10,997	10,997	10,997
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$100,036	$61,187	$61,187

Intangible_Assets_Licensing_Ri1

Intangible Assets - Licensing Rights (Details) (Licensing Rights [Member], USD $)	3 Months Ended		12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2011
Licensing Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Licence fee for the licensing rights			$200,000
Estimated useful life	7 years
Amortization expense		$7,143

Commitments_Narrative_Details

Commitments (Narrative) (Details) (USD $)	1 Months Ended	3 Months Ended		12 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2014	Aug. 31, 2013
Commitments [Abstract]
Rent expense on lease agreements	$15,000	$46,000	$45,000
Purchase obligations for signed agreements with contract research organizations and consultants		60,000
401(k) Retirement Savings Plan [Member]
Other Commitments [Line Items]
Employer contributions	5,000	20,000	16,000
Employee vesting percentage		100.00%
Annual non-elective safe harbor employer contribution		3.00%
Licensing Agreements [Member]
Other Commitments [Line Items]
License costs				200,000	25,000
Patent cost reimbursement		11,000	12,000
Common shares issued upon execution of license agreement					371,200
Common shared to be called by warrants					278,400
Aggregate milestone payments upon achievement of financing and development targets		6,020,000
Contingent milestone payments due upon achievement of sales target		57,025,000
Milestone payment				$100,000

Commitments_Schedule_of_Future

Commitments (Schedule of Future Minimum Lease Payments) (Details) (USD $)	Dec. 31, 2014
For The Year Ending September 30,
2015	$118,000
2016	59,000
Future minimum lease payments, total	$177,000

Share_Capital_Schedule_of_Tran

Share Capital (Schedule of Transactions In Share Capital) (Details) (USD $)	1 Months Ended		3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013
Share Capital [Abstract]
Proceeds from exercise of warrants and broker units	$727,804	$993,243	$938	$2,419,745
Transfer to common shares on exercise of warrants and broker units	890,214	1,212,985	426	5,035,567
Proceeds from exercise of options	11,488	168,270	27,781	137,969
Transfer to common shares on exercise of options	13,533	147,542	27,619	142,405
Share-based compensation	$36,509	$77,736	$86,865	$468,717
Number of common shares issued	1,151,000	13,701,770	126,800	4,217,101

Share_Capital_Schedule_of_Warr

Share Capital (Schedule of Warrants Activity) (Details)	1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Aug. 31, 2014	Aug. 31, 2014
	CAD	CAD	USD ($)	CAD
Share Capital [Abstract]
Number of Warrants, Beginning Balance	11,519,712	10,545,312	11,326,300	11,326,300
Number of Warrants Granted	42,600		38,100	38,100
Number of Warrants Granted			6,047,612	6,047,612
Number of Warrants Exercised	-1,017,000	-600	-5,832,300	-5,832,300
Number of Warrants Exercised			-60,000	-60,000
Number of Warrants Expired		-300
Number of Warrants, Ending Balance	10,545,312	10,544,412	11,519,712	11,519,712
Weighted Average Exercise Price, Beginning Balance	0.97	1.01		0.57
Weighted Average Exercise Price, Granted	0.75			0.46
Weighted Average Exercise Price, Granted			$1.33
Weighted Average Exercise Price, Exercised	0.75	0.75		0.68
Weighted Average Exercise Price, Exercised			$1.35
Weighted Average Exercise Price, Expired		0.75
Weighted Average Exercise Price, Ending Balance	1.01	1.04		0.97

Share_Capital_Summary_of_Outst

Share Capital (Summary of Outstanding Warrants) (Details)	Dec. 31, 2014	Sep. 30, 2014	Aug. 31, 2014	Aug. 31, 2013	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014
	CAD	CAD	CAD	CAD	Warrant One [Member]	Warrant Two [Member]	Warrant Three [Member]	Warrant Four [Member]	Warrant Six [Member]	Broker warrants [Member]	Broker warrants [Member]
					CAD	CAD	CAD	USD ($)	USD ($)	Warrant Five [Member]	Warrant Seven [Member]
										USD ($)	USD ($)
Class of Warrant or Right [Line Items]
Exercise Price	1.04	1.01	0.97	0.57	1.25	0.4	0.4	$1.35	$1.35	$1.05	$1.05
Number of Warrants	10,544,412	10,545,312	11,519,712	11,326,300	278,400	4,000,000	278,400	4,701,902	952,377	200,000	133,333
Expiry Date					23-Jan-15	25-Oct-15	4-Jan-16	9-Sep-16	20-Sep-16	9-Sep-16	20-Sep-16

Recovered_Sheet1

Share Capital (Schedule Of Warrants Exercised, Fair Value Assumptions) (Details) (Warrants Exercised [Member])	1 Months Ended	3 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Warrants Exercised [Member]
Class of Warrant or Right [Line Items]
Risk free interest rate	1.12%	1.12%	1.07%
Expected life (years)	11 days	4 days	3 months
Expected share price volitility	97.00%	97.00%	111.00%

Share_Capital_Schedule_of_Brok

Share Capital (Schedule of Broker Units Activity) (Details) (CAD)	1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Aug. 31, 2014
Share Capital [Abstract]
Number of units, Beginning Balance	551,200	467,200	596,200
Number of units, Exercised	-84,000	-1,200	-45,000
Number of units, Ending Balance	467,200	466,000	551,200
Weighted average exercise price, Beginning Balance	0.29	0.25	0.29
Weighted average exercise price, Exercised	0.5	0.5	0.33
Weighted average exercise price, Ending Balance	0.25	0.25	0.29

Share_Capital_Summary_of_Outst1

Share Capital (Summary of Outstanding Broker Units) (Details) (CAD)	3 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Aug. 31, 2014	Aug. 31, 2013
Class of Warrant or Right [Line Items]
Number of Units	466,000	467,200	551,200	596,200
Broker Unit One [Member]
Class of Warrant or Right [Line Items]
Exercise Price	0.25
Number of Units	400,000
Expiry Date	25-Oct-15
Broker Unit Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price	0.25
Number of Units	66,000
Expiry Date	4-Jan-16

Share_Capital_Schedule_of_Stoc

Share Capital (Schedule of Stock Option Activity) (Details)	1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Aug. 31, 2014	Aug. 31, 2014
	CAD	CAD	USD ($)	CAD
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance	5,935,533	5,885,533	6,588,868	6,588,868
Number of Options, Granted		102,500	195,000	195,000
Number of Options, Granted			595,000	595,000
Number of Options, Exercised	-50,000	-125,000	-1,441,668	-1,441,668
Number of Options, Expired			-1,667	-1,667
Number of Options, Ending Balance	5,885,533	5,863,033	5,935,533	5,935,533
Weighted Average Exercise Price, Beginning Balance	0.61	0.62		0.42
Weighted Average Exercise Price, Granted		1.52		1.42
Weighted Average Exercise Price, Granted			$1.83
Weighted Average Exercise Price, Exercised	0.25	0.25		0.41
Weighted Average Exercise Price, Expired				0.42
Weighted Average Exercise Price, Ending Balance	0.62	0.65		0.61

Share_Capital_Summary_of_Stock

Share Capital (Summary of Stock Options Outstanding and Exercisable) (Details)

Dec. 31, 2014

Sep. 30, 2014

Aug. 31, 2014

Aug. 31, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

2013 Fixed Stock Option Plan [Member]

Stock Option One [Member]

Stock Option Two [Member]

Stock Option Three [Member]

Stock Option Four [Member]

Stock Option Five [Member]

Stock Option Six [Member]

Stock Option Seven [Member]

Stock Option Eight [Member]

Stock Option Nine [Member]

Stock Option Ten [Member]

Stock Option Eleven [Member]

Stock Option Twelve [Member]

Stock Option Thirteen [Member]

Stock Option Fourteen [Member]

Stock Option Fifteen [Member]

Stock Option Sixteen [Member]

Stock Option Seventeen [Member]

Stock Option Eighteen [Member]

Stock Option Ninteen [Member]

Stock Option Twenty [Member]

Stock Option Twenty One [Member]

Stock Option Twenty Two [Member]

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

CAD

USD ($)

USD ($)

CAD

CAD

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

0.28

0.25

0.28

0.28

0.64

1

0.65

0.5

1.87

0.4

0.42

0.29

0.37

0.37

0.25

0.25

0.58

0.58

$1.83

$1.84

0.94

1.52

Number of Options

5,863,033

5,885,533

5,935,533

6,588,868

1,645,000

55,000

20,000

70,000

70,000

60,000

848,600

5,000

100,000

70,000

853,600

90,000

150,000

150,000

8,333

215,000

560,000

100,000

495,000

100,000

95,000

102,500

Exercisable at December 31, 2014

5,499,701

1,645,000

55,000

20,000

70,000

70,000

60,000

848,600

5,000

66,667

70,000

853,600

90,000

150,000

150,000

8,333

215,000

560,000

100,000

330,000

66,667

31,667

34,167

Expiry Date

9-Apr-17

17-May-17

28-Jun-17

13-Jul-17

25-Oct-17

10-Feb-18

8-Aug-18

26-Sep-18

7-Nov-18

22-Dec-18

13-Apr-19

18-Jun-19

9-Aug-19

16-Aug-19

23-Oct-19

19-Dec-19

14-May-20

23-May-20

1-Nov-20

15-Nov-20

27-Jun-21

12-Nov-21

Share_Capital_Schedule_of_Stoc1

Share Capital (Schedule of Stock Options Granted, Fair Value Assumptions) (Details) (Employee Stock Option [Member])	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.71%	1.98%
Expected life (years)	7 years	6 years 5 months 1 day
Expected share price volitility	116.00%	120.00%
Expected dividend yield	0.00%	0.00%

Share_Capital_Narrative_Detail

Share Capital (Narrative) (Details)	1 Months Ended	3 Months Ended								3 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014	Aug. 31, 2012	Dec. 31, 2014
	USD ($)	USD ($)	CAD	USD ($)	CAD	Broker units [Member]	Warrant [Member]	Performance Shares [Member]	Performance Shares [Member]	Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, shared reserved for issuance									10,000,000	10,000,000
Share based compensation, shares outstanding								3,838,383
Weighted average contractual life remaining on the outstanding warrants or broker units						10 months 2 days	1 year 3 months 18 days
Weighted average contractual life remaining on the outstanding options		3 years 11 months 9 days	3 years 11 months 9 days
Share based compensation, stock option vesting schedule										The exercise price of an option is set at the closing price of the Company's common shares on the date of grant. Stock options granted to directors, officers, employees and consultants are subject to the following vesting schedule: (a) One-third of the shares subject to the option shall vest immediately; (b) One-third of the shares subject to the option shall vest 12 months from the date of grant; and (c) One-third of the shares subject to the option shall vest 18 months from the date of grant. Stock options granted to investor relations consultants vest over a period of not less than 12 months with 25% of the shares subject to the option vesting on the date that is three months from the date of grant, and a further 25% vesting on each successive date that is three months from the date of the prior vesting.
Weighted average fair value of stock options awarded			1.34		1.49
Unrecognized share-based compensation expense		$175,000
Unrecognized share-based compensation expense, recognition period		1 year 6 months	1 year 6 months
Intrinsic value of the options exercised	1.74	1.15		1.55
Intrinsic value of the vested options		$0.83

Related_Party_Disclosures_Deta

Related Party Disclosures (Details) (USD $)	1 Months Ended	3 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Aug. 14, 2002
Director and Officer [Member] | Royalty Agreements [Member]
Related Party Transaction [Line Items]
Royalty percentage of gross receipts over base amount				5.00%
Gross receipt base amount for royalty calculation				$500,000
Royalty expense
A Taiwan Biopharmaceuticals Manufacturer and a Beneficial Owner [Member] | Collaborative Agreement [Member]
Related Party Transaction [Line Items]
Ownership percentage			5.00%

Supplemental_Disclosure_of_Cas2

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Schedule of Supplemental Disclosure of Cash Flow Information) (Details) (USD $)	1 Months Ended	3 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Cash paid during the period for taxes	$800	$9,800	$800
Cash paid during the period for interest

Supplemental_Disclosure_of_Cas3

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Schedule of Supplemental Disclosure of Non-cash Financing and Investing Activities) (Details) (USD $)	1 Months Ended		3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Transfer to common shares on exercise of warrants and broker units	$890,214	$1,212,985	$426	$5,035,567
Transfer to common shares on exercise of options	13,533	147,542	27,619	142,405
Shares subscribed transferred to common stock				$77,736

Concentrations_of_Credit_Risk_

Concentrations of Credit Risk (Details) (Customer Concentration Risk [Member])	1 Months Ended	3 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration risk percentage	81.00%	73.00%	76.00%
Product Sales and Contract Services Revenue [Member]
Concentration Risk [Line Items]
Concentration risk percentage	74.00%	71.00%	68.00%

Condensed_Transition_Period_Co1

Condensed Transition Period Comparable Year Financial Information (Balance Sheets) (Details) (USD $)	Dec. 31, 2014	Sep. 30, 2014	Aug. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Aug. 31, 2013
Assets [Abstract]
Cash and cash equivalents	$12,763,533	$13,769,953	$13,427,404	$16,725,570	$15,478,038	$7,859,889
Other current assets					225,713
Noncurrent assets	405,554	404,240	403,292		368,232
Total Assets	13,425,793	14,827,715	14,473,962		16,071,983
Liabilities and Equity [Abstract]
Accounts payable, accrued liabilities and deferred revenue					649,113
Warrant liability, including current portion					8,886,084
Shareholders' equity	9,236,842	10,464,735	7,700,633		6,536,786
Total Liabilities and Shareholders' Equity	$13,425,793	$14,827,715	$14,473,962		$16,071,983

Condensed_Transition_Period_Co2

Condensed Transition Period Comparable Year Financial Information (Statements of Operations) (Details) (USD $)	1 Months Ended		3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013
Condensed Transition Period Comparable Year Financial Information [Abstract]
Total Revenues	$52,786	$13,839	$212,661	$58,825
Expenses:
Cost of revenue		34,930
Research and development	178,280	203,367	418,821	548,225
General and administration	293,130	112,892	942,153	1,021,130
Total Expenses	505,109	351,189	1,538,075	1,754,432
Other Income (Loss)
Foreign exchange gain (loss)	-97,866	-106,446	-161,112	-16,508
Increase (decrease) in fair value of warrant liability	1,680,040	203,021	139,556	-3,880,195
Other income		386
Income tax expense	3,800		9,800	800
Net Income (Loss)	$1,127,904	($240,389)	($1,343,477)	($5,577,190)
Loss per common share - basic and diluted		$0
Weighted average number of common shares outstanding		65,873,540

Condensed_Transition_Period_Co3

Condensed Transition Period Comparable Year Financial Information (Statements of Cash Flows) (Details) (USD $)	1 Months Ended		3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013
Cash Flows Used In Operating Activities:
Net loss	$1,127,904	($240,389)	($1,343,477)	($5,577,190)
Adjustments and changes in working capital items		240,023
Net cash used in operating activities	-296,692	-366	-1,285,544	-1,086,888
Net cash used in investing activities	-15,968		404,062	-209,129
Net cash provided by financing activities	739,292	7,722,346	28,719	2,557,714
Effect of exchange rate changes on cash and cash equivalents	-84,083	-103,831	-153,657	-14,165
Net change in cash and cash equivalents	342,549	7,618,149	-1,006,420	1,247,532
Cash and cash equivalents - beginning of year	13,427,404	7,859,889	13,769,953	15,478,038
Cash and cash equivalents - end of year	$13,769,953	$15,478,038	$12,763,533	$16,725,570

Condensed_Transition_Period_Co4

Condensed Transition Period Comparable Year Financial Information (Share Capital Transactions) (Details) (USD $)	1 Months Ended		3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013
Condensed Transition Period Comparable Year Financial Information [Abstract]
Proceeds of private placements, net of issuance costs		$6,560,833
Proceeds from exercise of warrants and broker units	727,804	993,243	938	2,419,745
Transfer to common shares on exercise of warrants and broker units	890,214	1,212,985	426	5,035,567
Proceeds from exercise of options	11,488	168,270	27,781	137,969
Transfer to common shares on exercise of options	13,533	147,542	27,619	142,405
Share-based compensation	$36,509	$77,736	$86,865	$468,717
Number of common shares issued	1,151,000	13,701,770	126,800	4,217,101